Tighter restrictions for osteoporosis drug

Strontium ranelate should be restricted to a last-line therapy for osteoporosis and strictly avoided in patients with heart disease, the TGA has formally advised Australian doctors.

The changes to the drug's product information follow a recent European investigation, which imposed extra restrictions on the drug but stopped short of an outright ban.

The TGA has now confirmed that a black box warning will be added to strontium (Protos) in Australia, stating that it  "should only be used when other medications are considered unsuitable".